Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
Authors
de Boer, Richard HArrieta, Óscar
Yang, Chih-Hsin
Gottfried, Maya
Chan, Valorie
Raats, Johann
de Marinis, Filippo
Abratt, Raymond P
Wolf, Jürgen
Blackhall, Fiona H
Langmuir, Peter
Milenkova, Tsveta
Read, Jessica
Vansteenkiste, Johan
Affiliation
Western Hospital, Melbourne, Australia.Issue Date
2011-03-10
Metadata
Show full item recordAbstract
Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This randomized, placebo-controlled phase III study assessed the efficacy of vandetanib plus pemetrexed as second-line therapy in advanced non-small-cell lung cancer.Citation
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. 2011, 29 (8):1067-74 J. Clin. Oncol.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2010.29.5717PubMed ID
21282537Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2010.29.5717